Three cases of neuromyelitis optica spectrum disorder

被引:1
|
作者
Matsusue, Eiji [1 ]
Fujihara, Yoshio [1 ]
Suto, Yutaka [2 ]
Takahashi, Shotaro [2 ]
Tanaka, Kenichiro [2 ]
Nakayasu, Hiroyuki [2 ]
Nakamura, Kazuhiko [1 ]
Ogawa, Toshihide [3 ]
机构
[1] Tottori Prefectural Cent Hosp, Dept Radiol, 730 Ezu, Tottori, Tottori 6800901, Japan
[2] Tottori Prefectural Cent Hosp, Dept Neurol, Tottori, Tottori 6800901, Japan
[3] Tottori Univ, Div Radiol, Dept Pathophysiol Therapeut Sci, Tottori 680, Japan
来源
ACTA RADIOLOGICA OPEN | 2016年 / 5卷 / 05期
关键词
Neuromyelitis optica spectrum disorder; aquaporin-4 (AQP4); white matter lesions; extensive transverse myelitis; vasogenic edema; apparent diffusion coefficient;
D O I
10.1177/2058460116641456
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Neuromyelitis optica (NMO) is characterized by attacks of optic neuritis and longitudinally extensive transverse myelitis. Cases positive for aquaporin 4 antibodies are classified to NMO spectrum disorder (NMOSD) which includes cases with optic neuritis, transverse myelitis, or with brain lesions typical of NMO. Our three cases with NMO/NMOSD revealed five imaging features: (i) extensive transverse cord lesions, extending more than three vertebral segments, partially persisting as cavitation; (ii) periependymal lesions; (iii) lesions of the corticospinal tracts; (iv) extensive and confluent hemispheric white matter lesions reflecting vasogenic edema and partially involving the cerebral cortices and basal ganglia; and (v) two patterns of serial hemispheric white matter lesions: one is cavitation and another is partial regression or disappearance. Cavitations, in the upper spinal cord and hemispheric white matter, are considered to be caused by severe vasogenic edema and are likely to be one of the characteristic findings in NMOSD.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [22] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [23] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [24] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [25] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [26] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Simon Fung
    Matt Shirley
    CNS Drugs, 2023, 37 : 363 - 370
  • [27] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [28] Neuromyelitis Optica Spectrum Disorder Presented with Pseudoathetosis
    Seok, Hung Youl
    Eun, Mi-Yeon
    Jang, Seong Hwa
    You, Sooyeoun
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 419 - 419
  • [29] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798
  • [30] A new era for neuromyelitis optica spectrum disorder
    Silbermann, Elizabeth
    Bourdette, Dennis
    LANCET, 2019, 394 (10206): : 1304 - 1305